Catalent Pharma Solutions, a global drug delivery technology and advanced supply solutions company, and Supernus Pharmaceuticals have entered into an agreement by which Catalent is the supplier of Trokendi XRTM extended release capsules for Supernus.

Supernus developed Trokendi XR using its advanced drug delivery technology and transferred its formulation to Catalent for commercial manufacturing.      

Trokendi XR is a novel, oral, extended-release, once-daily formulation of topiramate for the treatment of epilepsy. Supernus recently received approval from the FDA and launched the product in the U.S. market.